Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intravenous (IV) infusion to the ...
MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...
In addition to OCREVUS, Roche has a diverse and promising pipeline of formulations and targets, such as Brainshuttle™ CD20 ...
People with multiple sclerosis (MS) may receive less frequent infusions of rituximab without increasing their chances of relapse or disease progression, according to a real-world study from Norway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback